Impact of Antiretroviral Treatment on Vaginal Microbiome Composition in People Living with HIV
This exploratory study of five women in Lagos, Nigeria, reveals that HIV-positive individuals exhibit a vaginal microbiome characterized by lower *Lactobacillus* abundance, higher prevalence of bacterial vaginosis-associated pathogens, and greater strain-level variability compared to HIV-negative controls, while suggesting that antiretroviral therapy may differentially influence microbial restoration across individuals.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, a vast and invisible world thrives, teeming with microscopic life that shapes our health in profound ways. One of the most critical of these hidden ecosystems is the vaginal microbiome, a community of bacteria that acts as a natural defense system. In a healthy state, this community is usually dominated by a specific type of beneficial bacteria called Lactobacillus. These helpful microbes produce lactic acid, creating an environment that keeps harmful invaders at bay and protects against infections, including the human immunodeficiency virus (HIV). When this balance is disrupted, a condition known as bacterial vaginosis can occur, where harmful bacteria take over, increasing the risk of acquiring or transmitting HIV. While scientists have long known that HIV infection itself alters this delicate balance, a crucial question remains unanswered: does the medication used to treat HIV, known as antiretroviral therapy, help restore this natural order, or does the damage persist?
In a small but detailed study conducted in Lagos, Nigeria, researchers set out to explore this question within a population that has been largely overlooked in previous research. The team focused on five women living in the city: three who were living with HIV and two who were HIV-negative. The researchers collected samples from the women's vaginas to map out the specific types of bacteria present. For the women with HIV, the study captured a snapshot of their microbial community before they started treatment and, for two of them, again one month after they began taking a standard combination of HIV medications. By using advanced sequencing technology that can read the entire genetic code of these bacteria, rather than just short fragments, the scientists were able to identify exactly which species were present and how their populations changed over time.
The results painted a clear picture of the differences between the two groups. In the women who were HIV-negative, the vaginal environment was largely dominated by Lactobacillus, the protective bacteria. In contrast, the women living with HIV showed a different landscape. Their samples contained significantly lower levels of the protective Lactobacillus and much higher levels of bacteria associated with bacterial vaginosis, such as Gardnerella and Prevotella. These harmful bacteria were found in all the HIV-positive samples, whereas they were either absent or present in only trace amounts in the healthy controls. The study also revealed that the bacterial communities in the women with HIV were far more chaotic and varied from person to person. While the healthy women shared a very similar, consistent mix of bacterial strains, the women with HIV had highly unique and unstable communities, suggesting that the virus creates a more unpredictable environment for these microscopic residents.
Perhaps the most intriguing finding emerged when the researchers looked at how the women responded to treatment. The study did not find a single, uniform reaction to the medication. Instead, the two women who provided follow-up samples showed completely different stories. One woman already had a high level of protective bacteria before starting treatment, and her levels remained high and stable after one month of medication. The other woman, however, started with almost no protective bacteria at all. Remarkably, after just one month of taking the HIV medication, her body shifted dramatically, and her protective Lactobacillus levels rose to nearly 100 percent, completely replacing the harmful bacteria. This suggests that while the medication can sometimes help restore a healthy balance, the outcome depends heavily on the individual's starting point. The medication did not act as a universal reset button; for some, it facilitated a rapid recovery, while for others, the environment remained unchanged.
Beyond the known bacteria, the researchers also discovered something unexpected. In their deep genetic scan, they identified dozens of bacterial sequences that did not match any known species in existing scientific databases. These were likely entirely new types of bacteria living in the vaginal environment of women in West Africa, a region where such microbial diversity has rarely been studied. The presence of these unknown organisms highlights how much remains to be learned about the human microbiome in different parts of the world.
This study serves as a vital first step, offering a glimpse into the complex relationship between HIV, its treatment, and the vaginal ecosystem in Nigeria. It confirms that women living with HIV in this region harbor a distinct microbial community that differs significantly from their HIV-negative peers, characterized by fewer protective bacteria and more harmful ones. It also suggests that the path to restoring a healthy balance after starting treatment is not the same for everyone. While the sample size was small, preventing broad generalizations, the findings provide a foundation for larger, more detailed investigations. Understanding these individual variations is essential for developing better strategies to support reproductive health and reduce the risk of HIV transmission in West African populations. The work underscores that the key to managing this invisible world may lie in recognizing that every person's microbial community is unique, requiring personalized attention rather than a one-size-fits-all approach.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.